Acute Myeloid Leukemia, in Relapse Clinical Trial
Official title:
LCCC 1522: Phase 2 Study of High Dose Cytarabine Followed by Pembrolizumab in Relapsed and Refractory Acute Myeloid Leukemia
Rationale:The purpose of this research study is to test the effectiveness of the standard high dose cytarabine (HiDAC) on days 1 through 5 followed by a single dose of pembrolizumab on day 14 as induction therapy in patients with relapsed and refractory acute myeloid leukemia (AML). Patients who achieve a response to treatment will continue on the study drug (pembrolizumab) every 3 weeks for up to 2 years maintenance therapy. Purpose:This is a study about a new investigative drug, pembrolizumab (MK-3475) that is being studied in a clinical research trial together with standard chemotherapy (HiDAC) in relapsed and refractory AML. The study will also explore the association between potential immune biomarkers and clinical outcomes with pembrolizumab; therefore all patients will have blood and bone marrow samples collected before and after treatment to determine the dynamic nature of immune signatures pre and post-treatment.
Primary Objective 1. Estimate the objective overall rate of CR (CR+CRi) for age-adjusted HiDAC (age <60 years: 2 gm/m2 IV Q12hours days 1-5; age >60 years: 1.5 gm/m2 IV Q12hours days 1-5) followed by pembrolizumab 200 mg IV on day 14 in relapsed and refractory AML patients Secondary Objectives 1. Estimate the rate of unacceptable toxicity associated with HiDAC followed by pembrolizumab as induction therapy 2. Estimate the objective overall response rates (PR+CR+CRi) for HiDAC followed by pembrolizumab. 3. Characterize the toxicity associated with HiDAC followed by pembrolizumab as induction therapy 4. Characterize the toxicity associated with pembrolizumab 200 mg IV Q3weeks when used as monotherapy maintenance after an initial response to induction phase HiDAC followed by pembrolizumab 5. Estimate the relapse-free survival (RFS) and progression-free survival (PFS) of patients receiving maintenance pembrolizumab 6. Estimate the overall survival (OS) of patients who received induction phase treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02204085 -
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06125652 -
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05105152 -
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
|
Phase 1 | |
| Recruiting |
NCT05597306 -
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT04898894 -
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05546580 -
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
|
Phase 1 | |
| Recruiting |
NCT03957915 -
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
|
Early Phase 1 | |
| Recruiting |
NCT05317403 -
Venetoclax to Augment Epigenetic Modification and Chemotherapy
|
Phase 1 | |
| Recruiting |
NCT04867928 -
Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
|
Phase 2 | |
| Completed |
NCT04402541 -
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
| Not yet recruiting |
NCT04716452 -
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05211570 -
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Terminated |
NCT03690154 -
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
|
Phase 1 | |
| Not yet recruiting |
NCT05854966 -
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 2 | |
| Not yet recruiting |
NCT06459024 -
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
|
||
| Recruiting |
NCT05735184 -
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
|
Phase 1 | |
| Recruiting |
NCT05124288 -
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
|
||
| Recruiting |
NCT05506332 -
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05949125 -
Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123
|
Phase 1 | |
| Recruiting |
NCT06128044 -
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 |